Compare TUSK & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TUSK | VTVT |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.3M | 148.7M |
| IPO Year | 2016 | 2015 |
| Metric | TUSK | VTVT |
|---|---|---|
| Price | $3.39 | $35.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $53.00 |
| AVG Volume (30 Days) | ★ 168.9K | 94.1K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 102.32 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $44,292,000.00 | N/A |
| Revenue This Year | $383.90 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.73 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.72 | $14.03 |
| 52 Week High | $3.92 | $44.00 |
| Indicator | TUSK | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 55.19 | 58.92 |
| Support Level | $2.54 | $33.57 |
| Resistance Level | $3.54 | $35.06 |
| Average True Range (ATR) | 0.14 | 1.84 |
| MACD | 0.03 | 0.34 |
| Stochastic Oscillator | 94.90 | 88.07 |
Mammoth Energy Services Inc is an integrated energy services company engaged in providing products and services to enable the exploration and development of North American onshore unconventional oil and natural gas reserves as well as the construction and repair of the electric grid for private utilities, public investor-owned utilities, and co-operative utilities through infrastructure services businesses. The company had three reportable segments, which includes rental services, infrastructure services, natural sand proppant services, accommodation services, and drilling services.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.